(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
2.10% $ 1.460
Live Chart Being Loaded With Signals
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States...
Stats | |
---|---|
Объем за сегодня | 164 571 |
Средний объем | 321 531 |
Рыночная капитализация | 78.68M |
EPS | $0 ( 2024-03-13 ) |
Дата следующего отчета о доходах | ( $-0.0700 ) 2024-05-09 |
Last Dividend | $0.0150 ( 2015-09-16 ) |
Next Dividend | $0 ( N/A ) |
P/E | 3.40 |
ATR14 | $0.00900 (0.62%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-01 | Keutzer Timothy | Buy | 239 731 | Common Stock |
2024-02-02 | Keutzer Timothy | Sell | 30 971 | Common Stock |
2024-02-02 | Mahadevia Ankit | Sell | 63 795 | Common Stock |
2024-02-01 | Joseph Tamara L | Buy | 239 731 | Common Stock |
2024-02-02 | Joseph Tamara L | Sell | 30 906 | Common Stock |
INSIDER POWER |
---|
59.10 |
Last 96 transactions |
Buy: 6 234 250 | Sell: 2 240 393 |
Объем Корреляция
Spero Therapeutics Inc Корреляция
10 Самые положительные корреляции | |
---|---|
AKYA | 0.855 |
COLB | 0.855 |
CARE | 0.85 |
ARQT | 0.842 |
CBAN | 0.835 |
FSEA | 0.833 |
FBMS | 0.832 |
FRBA | 0.826 |
FBIZ | 0.825 |
BIRD | 0.823 |
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Spero Therapeutics Inc Корреляция - Валюта/Сырье
Spero Therapeutics Inc Финансовые показатели
Annual | 2023 |
Выручка: | $96.74M |
Валовая прибыль: | $96.37M (99.62 %) |
EPS: | $0.430 |
FY | 2023 |
Выручка: | $96.74M |
Валовая прибыль: | $96.37M (99.62 %) |
EPS: | $0.430 |
FY | 2022 |
Выручка: | $48.58M |
Валовая прибыль: | $47.03M (96.82 %) |
EPS: | $-1.280 |
FY | 2021 |
Выручка: | $18.26M |
Валовая прибыль: | $0.00 (0.00 %) |
EPS: | $-2.91 |
Financial Reports:
No articles found.
Spero Therapeutics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0100 | 2010-03-30 |
Last Dividend | $0.0150 | 2015-09-16 |
Next Dividend | $0 | N/A |
Payout Date | 2015-10-07 | |
Next Payout Date | N/A | |
# dividends | 23 | -- |
Total Paid Out | $0.285 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.92 | -- |
Div. Sustainability Score | 7.56 | |
Div.Growth Potential Score | 0.385 | |
Div. Directional Score | 3.97 | -- |
Year | Amount | Yield |
---|---|---|
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.240 | 1.500 | 5.19 | 7.79 | [0 - 0.5] |
returnOnAssetsTTM | 0.130 | 1.200 | 5.66 | 6.79 | [0 - 0.3] |
returnOnEquityTTM | 0.339 | 1.500 | 7.34 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.53 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.42 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.05 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0304 | -1.500 | 9.49 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -20.59 | 1.000 | -8.74 | -8.74 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.623 | 2.00 | -0.208 | -0.415 | [0 - 30] |
freeCashFlowPerShareTTM | -0.623 | 2.00 | -0.311 | -0.623 | [0 - 20] |
debtEquityRatioTTM | 0.0519 | -1.500 | 9.79 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.811 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.200 | 1.000 | 8.00 | 8.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -5.95 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.542 | 0.800 | 9.72 | 7.78 | [0.5 - 2] |
Total Score | 7.56 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 3.26 | 1.000 | 9.77 | 0 | [1 - 100] |
returnOnEquityTTM | 0.339 | 2.50 | 8.29 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.623 | 2.00 | -0.208 | -0.623 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.623 | 2.00 | -0.208 | -0.415 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.00900 | 1.500 | -3.39 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.334 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | 0.385 |
Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа